TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 30-day frequency of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CROM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of noninvasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness in preventing invasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Improvement rate of abdominal and/or back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue boluses required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Observer's Assessment of Alertness and Sedation Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of TB disease
Endpoint domain: Mortality/survival
Primary endpoint: postprandial glucose response (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological effects of IV DMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hallucinogenic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of control
Endpoint domain: Adverse events/effects
Primary endpoint: Other Neuropsychiatric Symptoms (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychoactive Drug Use (PDU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unfavorable course of the disease
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ≥ 2 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: maximal voluntary contraction torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial median frequency at L5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slope during contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar flexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of iron incorporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exacerbation days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease severity index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking for transport duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to half-relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phosphorylation of phospholamban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MFIS scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity for diagnosis of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for diagnosis of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for diagnosis of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: movement time with decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at meetings
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: BUT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of injury assessed by corneal and conjunctival staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSVEP latency during retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of pimecrolimus compared to metronidazole and methylprednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects associated with pimecrolimus and metronidazole
Endpoint domain: Adverse events/effects
Primary endpoint: Total antioxidant power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8‐isoprostane level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new ACE/cerebral infarcts
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of MES
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: vocal stamina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate recovery from vocal loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessments of voice problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuropsychiatric symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastrointestinal problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: dose reductions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ten-year risk of fatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Time to any relapse
Endpoint domain: Mortality/survival
Primary endpoint: Half-life of variant LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of total irritable bowel syndrome symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PASI-75 score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waiting days for Internal Medicine consult
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS back pain at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS improvement of back pain at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-concordance with multilayer compression bandaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: no recurrence rate after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of postoperatory collateral effects
Endpoint domain: Adverse events/effects
Primary endpoint: healing rates of duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decrease in BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evidently effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nerve function injury improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of epsilon(4) allele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SI in NIDDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived healthiness of unhealthy products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intentions for buying unhealthy products
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reading nutrition facts panel
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wound hyperalgesia index at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of patients taking medications with alcohol interactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the plasma drug concentration-time profiles for rizatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma drug concentrations for rizatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-lives of rizatriptan and its N-monodesmethyl metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall misclassification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall false-positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall false-negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCI scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone formation rate per bone surface (BFR/BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of invasive ER-positive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Area under curve at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective drowsiness and clumsiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Organ failure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Potentially Inappropriate Medications (PO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of Cabozantinib
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3/4 adverse events (thrombocytopenia, leukopenia, deep vein thrombosis/pulmonary embolism)
Endpoint domain: Adverse events/effects
Primary endpoint: Eating rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality in the first month of follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of cardiovascular outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: long-term survival probability
Endpoint domain: Mortality/survival
Primary endpoint: risk of death after cystectomy for T2 or greater disease
Endpoint domain: Mortality/survival
Primary endpoint: MDA concentrations in parenteral nutrition admixtures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distance between hepatic parenchyma and stomach wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (biloma or stent migration)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o‐SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first significant flare following treatment cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: semantic accuracy in verbal modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: processing speed with living categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OABSS (Overactive Bladder Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasodilatory response to ACh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: forearm release of NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: FBF during NP infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Good improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting tremor severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrhythmic mortality
Endpoint domain: Mortality/survival
Primary endpoint: ACLS knowledge retention after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in ACLS knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean ELF concentrations of MXF, LEVO, and AZI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AM concentrations of MXF, LEVO, and AZI relative to MIC(90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MXF and LEVO concentrations relative to susceptibility breakpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior capsular opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: need for Nd:YAG laser posterior capsulotomy
Endpoint domain: Adverse events/effects
Primary endpoint: Influence of partners on attitudes toward child feeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-exercise energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess post-exercise oxygen consumption (EPOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean PHQ-9 depression symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the steady state plasma concentration-time curve (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance of empagliflozin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alteration in free T3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in MSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lesions with or without epithelial disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Local toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Test-retest variability of visual acuity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding requiring medical attention
Endpoint domain: Adverse events/effects
Primary endpoint: Depression screening using SADQ H10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tachycardia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial ischaemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of anxiety levels in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of parents' distress rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quadriceps peak torque (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hamstrings peak torque (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: absolute change in maximal platelet aggregation (ΔAgg(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of high posttreatment platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight‐bearing distribution during quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body sway during standing on foam surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement velocity during limit of stability test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of analgesia compared to cold sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in global BPRS score after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with high CGI-S scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with low CGI-S scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic equivalence between devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in daily walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-surgical cTnI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cervical flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain disability in everyday life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: achievement of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of serum lipid metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Open-field score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: substantial postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate of SIMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participation in practical and social activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Castrate levels of testosterone maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prostate-specific antigen levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best overall response rates according to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean percent change from baseline FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean total daily asthma-related cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of CD57 + NK T cells at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of decline in total hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HIV‐1 RNA levels less than 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of 25‐hydroxyvitamin D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of primary colorectal cancers
Endpoint domain: Mortality/survival
Primary endpoint: Consumption of fruit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Tinnitus Questionnaire (Mini-TQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pruritus reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year functional outcomes (Mayo and QuickDASH score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1-year post-index procedure radiographic findings (radial height, radial inclination, volar tilting, ulnar variance, and articular step-off)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial lipemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inflammation markers (IL-1ra, IL-4, IL-5, IL-6, IL-10, TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 7dPP tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypotension requiring vasopressors
Endpoint domain: Adverse events/effects
Primary endpoint: esophageal acid exposure (%time pH <4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastric acidity (%time pH <4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of acid GER episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes